SCHEDULE: Armistice Capital Discloses 7.16% Stake in Aethlon Medical
Beneficial Ownership Report
Armistice Capital, LLC and Steven Boyd have disclosed a beneficial ownership of 7.16% in Aethlon Medical Inc.'s common stock.
Summary
- Armistice Capital, LLC and Steven Boyd, collectively referred to as the "Reporting Persons," have filed an Amendment No. 1 to Schedule 13G.
- The filing reports beneficial ownership of 185,000 shares of Aethlon Medical Inc. common stock.
- This ownership represents 7.16% of the company's outstanding common stock.
- The percentage is based on 2,585,316 shares outstanding as of June 24, 2025, as reported in Aethlon Medical's Form 10-K filed on June 26, 2025.
- Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
- Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
- Both reporting persons share voting and dispositive power over the 185,000 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of beneficial ownership by an institutional investor, Armistice Capital, and its managing member, Steven Boyd. It indicates their significant stake in Aethlon Medical Inc., a company in the medical sector. Such disclosures are common and reflect investment decisions rather than broader industry trends, though a new or increased stake can signal investor confidence in the company's prospects within its industry.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake (7.16%) by Armistice Capital and Steven Boyd may be viewed positively, signaling institutional confidence or interest in Aethlon Medical Inc.
Key Dates
| Date | Description |
|---|---|
| 06/24/2025 | Date of shares outstanding calculation (2,585,316 shares) as reported in Issuer's Form 10-K. |
| 06/26/2025 | Date Issuer's Form 10-K was filed with the SEC. |
| 06/30/2025 | Date of event which requires filing of this statement. |
| 08/14/2025 | Date of filing of this Schedule 13G Amendment No. 1. |
Keywords
Aethlon Medical, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.